New drug hope for hepatitis C sufferers

A cocktail of three drugs, including a new class of antiviral agent, has shown encouraging results in treating hepatitis C, a disease which attacks the liver, a study said Wednesday.

"This study represents a remarkable advance and a potential cure for people with hepatitis C who have not responded to previous therapy," said co-author Stuart Gordon, from the Henry Ford Hospital in Detroit.

"This study ushers in a new era of drug development that will provide a host of antiviral agents to treat hepatitis C, and we are now witnessing dramatic and rapid advances in how we will be able to treat these patients."

The results published in the March 31 edition of the New England Journal of Medicine reveal the effectiveness of a drug called boceprevir in treating hepatitis C, a chronic viral disease affecting some 3.2 million Americans.

In the past the disease could be spread through contact with infected blood products, and is still contracted by drug users sharing needles or straws during the use of cocaine, or by unprotected sex with a sufferer.

There is currently no vaccine for the hepatitis C virus, and the Centers for Disease Control and Prevention estimates that more than 12,000 people die each year of liver disease and liver cancer associated with the illness.

Most people infected with the disease live symptom-free for years, but once it is discovered it is often too late for it to respond to the current two-drug treatment.

In the study, more than 1,000 patients from several countries including the United States and Canada were divided into three groups.

All three groups received the current two-drug treatment of peginterferon and ribavirine (Rebetol) for four weeks.

One control group then continued to take the same treatment for another 44 weeks, a second group added boceprevir to the two other drugs for 32 weeks, and a third group took the three-drug cocktail for 44 weeks.

The two groups which received doses of boceprevir showed a better response, and in some cases the virus even disappeared from their blood.

Boceprevir specifically targets the hepatitis C virus and inhibits it from replicating in the patient's body. In group two, 59 percent of patients responded to the treatment and in group three in 66 percent.

A virological response is generally taken to mean the virus has been wiped out from the patient's body.

Boceprevir, which has been developed by Merck, is currently undergoing review before being approved for general use by the Food and Drug Administration.

js/jkb/jm

 

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Ecommerce Manager

    £45000 - £55000 per annum: Recruitment Genius: An opportunity is available to ...

    Recruitment Genius: Customer Service / Administrator - Spanish Speaking

    £16000 - £17000 per annum: Recruitment Genius: This world leading specialist i...

    Recruitment Genius: Regional Support Manager

    Negotiable: Recruitment Genius: This role's responsibility also include operat...

    Recruitment Genius: Field Engineer - Northern Home Counties

    £27000 - £28000 per annum: Recruitment Genius: Their revenue and profit have g...

    Day In a Page

    Greece debt crisis: What happened to democracy when it’s a case of 'Vote Yes or else'?

    'The economic collapse has happened. What is at risk now is democracy...'

    If it doesn’t work in Europe, how is it supposed to work in India or the Middle East, asks Robert Fisk
    The science of swearing: What lies behind the use of four-letter words?

    The science of swearing

    What lies behind the use of four-letter words?
    The Real Stories of Migrant Britain: Clive fled from Zimbabwe - now it won't have him back

    The Real Stories of Migrant Britain

    Clive fled from Zimbabwe - now it won’t have him back
    Africa on the menu: Three foodie friends want to popularise dishes from the continent

    Africa on the menu

    Three foodie friends want to popularise dishes from the hot new continent
    Donna Karan is stepping down after 30 years - so who will fill the DKNY creator's boots?

    Who will fill Donna Karan's boots?

    The designer is stepping down as Chief Designer of DKNY after 30 years. Alexander Fury looks back at the career of 'America's Chanel'
    10 best statement lightbulbs

    10 best statement lightbulbs

    Dare to bare with some out-of-the-ordinary illumination
    Wimbledon 2015: Heather Watson - 'I had Serena's poster on my wall – now I'm playing her'

    Heather Watson: 'I had Serena's poster on my wall – now I'm playing her'

    Briton pumped up for dream meeting with world No 1
    Wimbledon 2015: Nick Bollettieri - It's time for big John Isner to produce the goods to go with his thumping serve

    Nick Bollettieri's Wimbledon Files

    It's time for big John Isner to produce the goods to go with his thumping serve
    Dustin Brown: Who is the tennis player who knocked Rafael Nadal out of Wimbeldon 2015?

    Dustin Brown

    Who is the German player that knocked Nadal out of Wimbeldon 2015?
    Ashes 2015: Damien Martyn - 'England are fired up again, just like in 2005...'

    Damien Martyn: 'England are fired up again, just like in 2005...'

    Australian veteran of that Ashes series, believes the hosts' may become unstoppable if they win the first Test
    Tour de France 2015: Twins Simon and Adam Yates have a mountain to climb during Tour of duty

    Twins have a mountain to climb during Tour of duty

    Yates brothers will target the steepest sections in bid to win a stage in France
    John Palmer: 'Goldfinger' of British crime was murdered, say police

    Murder of the Brink’s-MAT mastermind

    'Goldfinger' of British crime's life ended in a blaze of bullets, say police
    Forget little green men - aliens will look like humans, says Cambridge University evolution expert

    Forget little green men

    Leading evolutionary biologist says aliens will look like humans
    The Real Stories of Migrant Britain: An Algerian scientist adjusts to life working in a kebab shop

    The Real Stories of Migrant Britain

    An Algerian scientist struggles to adjust to her new life working in a Scottish kebab shop
    Bodyworlds museum: Dr Gunther von Hagens has battled legal threats, Parkinson's disease, and the threat of bankruptcy

    Dying dream of Doctor Death

    Dr Gunther von Hagens has battled legal threats, Parkinson's disease, and the threat of bankruptcy